키나제 억제제로서 푸리논 화합물
    1.
    发明公开
    키나제 억제제로서 푸리논 화합물 审中-公开
    嘌呤化合物作为激酶抑制剂

    公开(公告)号:KR20180030730A

    公开(公告)日:2018-03-23

    申请号:KR20187007316

    申请日:2013-01-30

    CPC classification number: C07D473/34

    Abstract: 브루톤티로신키나제(Btk)와공유결합을형성하는화합물이본원에개시되어있다. Btk의비가역적억제제도기재되어있다. 또한, Btk의가역적억제제도기재되어있다. 상기화합물을포함하는약학조성물도개시되어있다. 자가면역질환또는병태, 이종면역질환또는병태, 림프종을포함하는암, 및염증성질환또는병태의치료를위해 Btk 억제제를단독으로또는다른치료제와함께사용하는방법이개시되어있다.

    Abstract translation: 本文公开了与布鲁顿酪氨酸激酶(Btk)形成共价键的化合物。 还描述了Btk的不可逆抑制剂。 另外,还描述了Btk的可逆抑制剂。 还公开了包含该化合物的药物组合物。 单独或与其他治疗剂组合使用Btk抑制剂的方法用于治疗自身免疫疾病或病症,异质性免疫疾病或病症,癌症(包括淋巴瘤)和炎性疾病或病症。

    PURINONE COMPOUNDS AS KINASE INHIBITORS
    3.
    发明公开
    PURINONE COMPOUNDS AS KINASE INHIBITORS 审中-公开
    PURINONVERBINDUNGEN作为激酶抑制剂

    公开(公告)号:EP3016953A4

    公开(公告)日:2017-03-01

    申请号:EP14819592

    申请日:2014-06-30

    CPC classification number: C07D473/34 A61K31/52

    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

    INHIBITORS OF BRUTON`S TYROSINE KINASE

    公开(公告)号:PH12016500575A1

    公开(公告)日:2016-07-25

    申请号:PH12016500575

    申请日:2016-03-29

    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Patent Agency Ranking